Less Ads, More Data, More Tools Register for FREE

Pin to quick picks4basebio Plc Regulatory News (4BB)

Share Price Information for 4basebio Plc (4BB)

Share Price is delayed by 15 minutes
Get Live Data
547.50    0.00 (0.00%)
Bid:
520.00
Ask:
575.00
Spread: 55.00 (10.577%)
Market Cap: £84.78m
4BB Live PriceLast checked at - London Stock Exchange

Intraday 4basebio Plc Share Chart

Director/PDMR Shareholding

26 Feb 2021 07:00

4basebio UK Societas - Director/PDMR Shareholding

4basebio UK Societas - Director/PDMR Shareholding

PR Newswire

London, February 25

26 February 2021

4basebio UK Societas

(the "Company")

Director’s Dealing

4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on exploiting its intellectual property in the field of gene therapies and DNA vaccines, announces that, on 25 February 2021, Heikki Lanckriet, chief executive officer, acquired 3,000 ordinary shares at an average price of 345 pence per share on behalf of persons closely associated with him.

As a result of the acquisition of ordinary shares, Heikki Lanckriet’s beneficial holding, including shares held by persons closely associated with him, comprises 1,240,003 ordinary shares representing 10.07 per cent. of the Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio UK Societas Heikki Lanckriet+44 (0)1223 967 943
Nominated Adviser Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson+44 (0)20 7213 0880
Broker finnCap Ltd Geoff Nash/Richard Chambers/Charlotte Sutcliffe+44 (0)20 7220 0500

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1Details of the person discharging managerial responsibilities/person closely associated
a.NameHeikki Lanckriet
2Reason for notification
a.Position/StatusChief Executive Officer
b.Initial notification/ AmendmentInitial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.Name4basebio UK Societas
b.LEI2138005D5SAG8FIR6G91
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.Description of the financial instrument, type of instrument Identification CodeOrdinary Shares ISIN: GB00BLD8ZL39
b.Nature of the transactionAcquisition of ordinary shares
c.Price(s) and volume(s)
Volume(s)Price (p)
1,000 1,000 1,000345p 345p 345p
d.Aggregated information - Aggregated Volume - Price -3,000 -345 pence per share
e.Date of the transaction25/2/2021
f.Place of the transactionLondon Stock Exchange, AIM
Date   Source Headline
22nd May 20269:10 amPRNDirector Dealing
20th May 20267:02 amPRNFinal Results and Notice of AGM
20th May 20267:00 amPRN4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
14th May 20267:00 amPRNAppointment of Chief Financial Officer and Board Changes
11th May 20267:00 amPRN4basebio Launches Enzymatic ssDNA Platform
31st Mar 20267:00 amPRNLease of Manufacturing Facility
12th Mar 20267:00 amPRNAppointment of COO
3rd Mar 20267:00 amPRNAppointment of CCO
16th Feb 20267:00 amPRNDirector Dealing
11th Feb 20263:58 pmPRNDirector Dealing
10th Feb 20267:00 amPRNLeadership Changes
27th Oct 20257:00 amPRNSynthetic opDNA® utilised in Phase I/II US clinical trials
10th Oct 202511:30 amPRNResult of Extraordinary General Meeting
30th Sep 20254:20 pmPRNDirector Dealing
29th Sep 20257:00 amPRNHalf-year Report
22nd Jul 20257:00 amPRNEmployee Long Term Incentive Plan and Issue of Equity
8th Jul 202510:30 amPRNDirector Appointment, Board Change
3rd Jul 20257:00 amPRNHolding(s) in Company
3rd Jul 20257:00 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNHolding(s) in Company
27th Jun 20256:05 pmPRNResult of AGM
25th Jun 20257:00 amPRNExercise of Options
17th Jun 20257:00 amPRNHolding(s) in Company
17th Jun 20257:00 amPRNHolding(s) in Company
27th May 20257:00 amPRNFinal Results and Notice of AGM
4th Apr 202512:00 pmPRNDirector Dealing
2nd Apr 20257:00 amPRN4basebio Receives GMP Licence for its UK DNA Manufacturing Facility
25th Mar 202510:15 amPRNHolding(s) in Company
14th Mar 20257:00 amPRNRBC Capital Markets initiates research coverage
7th Mar 20257:00 amPRNEmployee Long Term Incentive Plan and Issue of Equity
3rd Mar 20254:37 pmPRNDirector's Dealing
8th Jan 20257:00 amPRNAppointment of Chief Commercial Officer
17th Dec 20247:00 amPRNDirectorate Change
29th Nov 202412:30 pmPRNDirector's Dealing
19th Nov 20242:15 pmPRNDirector's Dealing
15th Nov 20245:31 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20247:00 amPRNHolding(s) in Company
14th Nov 20247:00 amPRNAppointment of Joint Corporate Broker
12th Nov 20247:00 amPRNCompletion of Strategic Investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.